drugset / Trial / NCT04671056

Drug Interaction Study of MGL-3196 With Pioglitazone

NCT04671056

Phase 1 Completed 16 enrolled Madrigal Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.

Timeline

Start
2018-11-09
Primary completion
2018-12-11
Completion
2019-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 15 mg Oral
Subject Resmetirom Small molecule 100 mg Oral

Indications

No indication recorded.